Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing --
-- Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration --
-- Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. --
-- Arcellx to continue independently progressing its development pipeline and researching new product candidates beyond myeloma --
-- Arcellx to host a conference call and webcast today at 5:45 a.m. PT --
REDWOOD CITY, Calif., and SANTA MONICA, Calif., Dec. 9, 2022 /PRNewswire/ -- Arcellx
